PPBT — Purple Biotech Income Statement
0.000.00%
Last trade - 00:00- $5.49m
- -$0.28m
Annual income statement for Purple Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 13.2 | 17.9 | 22.6 | 22.3 | 11 |
| Operating Profit | -13.2 | -17.9 | -22.6 | -22.3 | -11 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -28.7 | -17.8 | -21.8 | -20 | -7.28 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -28.7 | -17.8 | -21.8 | -20 | -7.28 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -28 | -18.4 | -21.7 | -19.9 | -7.24 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28 | -18.4 | -21.7 | -19.9 | -7.24 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.249 | -0.101 | -0.12 | -0.079 | -0.021 |
| Dividends per Share |